Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab versus rivaroxaban in atrial fibrillation
2020-004507-13Phase 2Active
- Sponsor
- Anthos Therapeutics
- Start
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abelacimab and rivaroxaban in Atrial fibrillation (AFib) (3 arms), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of composite of ISTH-defined major bleeding or clinically relevant non-major bleeding. Started Dec 2020; status: active.
02
Drugs
abelacimabrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2020-004507-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004507-13.